UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July~~August 206, 2021

Soliton, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-38815	36-4729076
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

5304 Ashbrook Drive

Houston, Texas 77081

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (844) 705-4866

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


			☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


			☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbols(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	SOLY	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 58.0701. ~~Submission~~Other ~~of Matters to a Vote of Security Holders~~Events.

As previously disclosed, on May 8, 2021, Soliton, Inc. a Delaware corporation (the “Company”), ~~held~~entered ainto ~~special~~an ~~meeting~~Agreement ofand ~~stockholders~~Plan onof ~~July~~Merger ~~20, 2021~~ (the “~~special~~Merger ~~meeting~~Agreement”). Atwith ~~the~~AbbVie ~~special~~Inc. ~~meeting,~~(“AbbVie”) ~~the~~and ~~Company’s~~Scout ~~stockholders~~Merger ~~approved~~Sub, ~~the proposal described below~~Inc., ~~Stockholder action on~~ a ~~second~~wholly ~~proposal,~~owned tosubsidiary ~~approve one or more adjournments~~ of ~~the~~AbbVie ~~special~~(“Merger ~~meeting~~Sub”), ifpursuant ~~necessary~~to orwhich ~~appropriate,~~Merger toSub ~~permit~~will ~~further~~merge ~~solicitation~~with ofand ~~proxies~~into inthe ~~favor~~Company, ofwith ~~proposal~~the 1,Company ~~was~~continuing ~~not~~as ~~required~~the surviving corporation and noa ~~vote~~wholly ~~was~~owned ~~taken~~subsidiary onof ~~that~~AbbVie ~~proposal~~(the “Merger”).

~~The~~In ~~final~~connection ~~voting~~with ~~results~~the proposed Merger, on June 2, 2021, the Company and AbbVie each filed the requisite notification and report forms (each, an “HSR Notification”) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with ~~respect~~the toAntitrust Division of the ~~proposal~~Department ~~voted~~of ~~upon~~Justice and the Federal Trade Commission (“FTC”). Following informal discussions with the staff at the ~~special~~FTC, ~~meeting~~AbbVie ~~are~~and ~~set~~the ~~forth~~Company ~~below~~agreed to voluntarily provide the FTC with additional time in which to review the Merger and AbbVie, as the acquiring party, voluntarily withdrew its HSR Notification on July 2, 2021 and refiled its HSR Notification on July 7, 2021.

~~Proposal~~On 1August 6, 2021, the Company and AbbVie each received a request for additional information and documentary material (the "Second Request") from the FTC in connection with the FTC's review of the transactions contemplated by the Merger Agreement. The effect of the Second Request is to extend the waiting period imposed by the HSR Act until 30 days after the Company and AbbVie have certified substantial compliance with the Second Request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC. The Company and AbbVie continue to work cooperatively with the FTC staff in its review of the proposed transaction, and continue to expect to complete the transaction in the second half of 2021, subject to the satisfaction or permitted waiver of the conditions to closing.

~~The~~Forward-Looking Company’s stockholders adopted the Agreement and Plan of Merger, dated as of May 8, 2021 and as it may be amended or supplemented (the “Merger Agreement”), by and among the Company, AbbVie Inc., a Delaware corporation (“AbbVie”), and Scout Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of AbbVie (“Merger Sub”), pursuant to which Merger Sub will be merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of AbbVie.Statements

For						Against						Abstentions
14,661,235						519,246						303,469

This communication, and any documents to which the Company refers in this communication, contain not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often include the words “forecast,” “expect,” “believe,” “will,” “intend,” “plan,” and words of similar substance. Such forward-looking statements include the expected completion and timing of the proposed transaction and other information relating to the proposed transaction. Such forward-looking statements are subject to risks and uncertainties that could cause actual results or performance to differ materially from those expressed in or contemplated by the forward-looking statements, including the following: (i) the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect the Company’s business and the price of the Company’s common stock, (ii) the failure to satisfy any of the conditions to the consummation of the proposed transaction, including the receipt of certain governmental and regulatory approvals, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, (iv) the outcome of any legal proceedings that have been or may be instituted against the Company related to the Merger Agreement or the proposed transaction and (v) other risks described in the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update or revise publicly the information in this communication, whether as a result of new information, future events or otherwise, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			SOLITON, INC.


			By:			/s/ Lori Bisson
						Lori Bisson
						Executive Vice-President and
						Chief Financial Officer

Dated: ~~July~~August 206, 2021

Filing Compare · Soliton, Inc.